Novo Nordisk H1 Profit Up

Danish pharmaceutical company Novo Nordisk A/S (NVO) Wednesday reported first-half net profit of 24.75 billion Danish krone or 10.71 krone per share, up from last year's 22.52 billion krone or 9.58 krone per share.

Novo Nordisk's operating profit dropped 1 percent to 29.76 billion krone from last year's 30.14 billion krone.

Net sales rose 5% to 66.85 billion krone from last year's 63.88 billion krone.

Sales in International Operations increased by 7% and North America Operations increased by 1%.

For the 2021 outlook, sales growth is now expected to be 10-13% at constant exchange rates and operating profit growth is now expected to be 9-12%, up from prior forecast of sales growth of 6-10% and operating profit of 5-9%.

CEO Lars Fruergaard Jørgensen said, "We are pleased with the sales growth in the first half of 2021. The growth is driven by all geographical areas within International Operations as well as North America Operations, and by all therapy areas, in particular by our portfolio of GLP-1 treatments. Within R&D, we reached a very important milestone with the approval of Wegovy in the US, offering people living with obesity a new, efficacious treatment option. The strong financial performance in the first half of 2021 and the initial substantial demand for Wegovy in the US have enabled us to raise our outlook for the full year."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT